Shares of Genmab A/S (CPH:GEN) shot up 11 percent Thursday after the company reported that the phase III ALCYONE study of daratumumab (Darzalex) met the primary endpoint of improving progression-free survival (PFS) as front-line treatment for newly diagnosed multiple myeloma (MM) patients.